

Natalja T Ter Haar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7117305/publications.pdf>

Version: 2024-02-01

19
papers

917
citations

687363

13
h-index

888059

17
g-index

19
all docs

19
docs citations

19
times ranked

1613
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment. <i>Gynecologic Oncology</i> , 2022, 164, 577-586. | 1.4 | 54 |
| 2 | The RAD51-FFPE Test; Calibration of a Functional Homologous Recombination Deficiency Test on Diagnostic Endometrial and Ovarian Tumor Blocks. <i>Cancers</i> , 2021, 13, 2994. | 3.7 | 23 |
| 3 | Abstract 364: The RAD51-FFPE test rapidly and reliably identifies homologous recombination deficient ovarian and endometrial carcinomas. , 2021, , . | | 0 |
| 4 | Histological and Somatic Mutational Profiles of Mismatch Repair Deficient Endometrial Tumours of Different Aetiologies. <i>Cancers</i> , 2021, 13, 4538. | 3.7 | 8 |
| 5 | The RECAP Test Rapidly and Reliably Identifies Homologous Recombination-Deficient Ovarian Carcinomas. <i>Cancers</i> , 2020, 12, 2805. | 3.7 | 30 |
| 6 | Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas. <i>Clinical Cancer Research</i> , 2019, 25, 1087-1097. | 7.0 | 113 |
| 7 | The landscape of somatic mutations in Indonesian cervical cancer is predominated by the PI3K pathway. <i>Gynecologic Oncology</i> , 2018, 148, 189-196. | 1.4 | 9 |
| 8 | Validation and Implementation of BRCA1/2 Variant Screening in Ovarian Tumor Tissue. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 600-611. | 2.8 | 18 |
| 9 | Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas – an ENITEC Group Initiative. <i>Clinical Cancer Research</i> , 2017, 23, 1274-1285. | 7.0 | 30 |
| 10 | Genomic Characterization of Vulvar (Pre)cancers Identifies Distinct Molecular Subtypes with Prognostic Significance. <i>Clinical Cancer Research</i> , 2017, 23, 6781-6789. | 7.0 | 110 |
| 11 | L1 cell adhesion molecule (L1CAM) is a strong predictor for locoregional recurrences in cervical cancer. <i>Oncotarget</i> , 2017, 8, 87568-87581. | 1.8 | 9 |
| 12 | Precise Classification of Cervical Carcinomas Combined with Somatic Mutation Profiling Contributes to Predicting Disease Outcome. <i>PLoS ONE</i> , 2015, 10, e0133670. | 2.5 | 48 |
| 13 | Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, 402. | 6.3 | 229 |
| 14 | Incidence Changes of Human Papillomavirus in Oropharyngeal Squamous Cell Carcinoma and Effects on Survival in the Netherlands Cancer Institute, 1980-2009. <i>Anticancer Research</i> , 2015, 35, 4015-22. | 1.1 | 19 |
| 15 | CDKN2A(p16) and HRAS are frequently mutated in vulvar squamous cell carcinoma. <i>Gynecologic Oncology</i> , 2014, 135, 149-155. | 1.4 | 52 |
| 16 | High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma. <i>Gynecologic Oncology</i> , 2014, 133, 197-204. | 1.4 | 70 |
| 17 | Designing a High-Throughput Somatic Mutation Profiling Panel Specifically for Gynaecological Cancers. <i>PLoS ONE</i> , 2014, 9, e93451. | 2.5 | 39 |
| 18 | Cyclin D1 gene amplification and overexpression are present in ductal carcinoma in situ of the breast. , 1999, 187, 279-284. | | 54 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Cyclin D1 gene amplification and overexpression are present in ductal carcinoma in situ of the breast. Journal of Pathology, 1999, 187, 279-284. | 4.5 | 2 |